Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3BAE

Crystal structure of Fab WO2 bound to the N terminal domain of Amyloid beta peptide (1-28)

3BAE の概要
エントリーDOI10.2210/pdb3bae/pdb
分子名称WO2 IgG2a Fab fragment Light Chain Kappa, WO2 IgG2a Fab fragment Heavy Chain, Amyloid Beta Peptide, ... (4 entities in total)
機能のキーワードabeta, amyloid beta peptide, fab, wo2, alzheimer's disease, immunotherapies, app, immune system
由来する生物種Mus musculus (house mouse)
詳細
タンパク質・核酸の鎖数3
化学式量合計52246.20
構造登録者
Miles, L.A.,Wun, K.S.,Crespi, G.A.,Parker, M.W. (登録日: 2007-11-07, 公開日: 2008-04-15, 最終更新日: 2024-11-20)
主引用文献Miles, L.A.,Wun, K.S.,Crespi, G.A.,Fodero-Tavoletti, M.T.,Galatis, D.,Bagley, C.J.,Beyreuther, K.,Masters, C.L.,Cappai, R.,McKinstry, W.J.,Barnham, K.J.,Parker, M.W.
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.
J.Mol.Biol., 377:181-192, 2008
Cited by
PubMed Abstract: Alzheimer's disease (AD) is the most common form of dementia. Amyloid-beta (A beta) peptide, generated by proteolytic cleavage of the amyloid precursor protein, is central to AD pathogenesis. Most pharmaceutical activity in AD research has focused on A beta, its generation and clearance from the brain. In particular, there is much interest in immunotherapy approaches with a number of anti-A beta antibodies in clinical trials. We have developed a monoclonal antibody, called WO2, which recognises the A beta peptide. To this end, we have determined the three-dimensional structure, to near atomic resolution, of both the antibody and the complex with its antigen, the A beta peptide. The structures reveal the molecular basis for WO2 recognition and binding of A beta. The A beta peptide adopts an extended, coil-like conformation across its major immunodominant B-cell epitope between residues 2 and 8. We have also studied the antibody-bound A beta peptide in the presence of metals known to affect its aggregation state and show that WO2 inhibits these interactions. Thus, antibodies that target the N-terminal region of A beta, such as WO2, hold promise for therapeutic development.
PubMed: 18237744
DOI: 10.1016/j.jmb.2007.12.036
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.593 Å)
構造検証レポート
Validation report summary of 3bae
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon